ホーム > 藤澤 康弘/ Fujisawa, Yasuhiro

藤澤 康弘

ALUMNI 2025年3月現在、筑波大学が主たる所属機関ではありません

Fujisawa, Yasuhiro

医学医療系 , 准教授
Faculty of Medicine , Associate Professor
オープンアクセス版の論文は「つくばリポジトリ」で読むことができます。
  1. 1. A Case of Recurrent Atypical Lipomatous Tumor. Keisuke Anju; Kazumasa Oya; Yoshiyuki Ishii; Yasuhiro Fujisawa
      The American Journal of dermatopathology 47: 81 (2025) Semantic Scholar
  2. 2. 自己免疫疾患で生じる皮膚炎の加齢で変化する病態制御機構 大矢 和正; 中村 貴之; 沖山 奈緒子; 藤澤 康弘乃村 俊史
      加齢皮膚医学セミナー 19: 9 (2024)
  3. 3. Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes. Yusuke Muto; Yumi Kambayashi; Hiroshi Kato; Satoru Mizuhashi (+13 著者) Taku Fujimura
      Cancers 16: (2024) Semantic Scholar
  4. 4. Phase II, multicenter study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-PD-1 antibody-refractory malignant melanoma: TM5614-MM trial. Taku Fujimura; Koji Yoshino; Hiroshi Kato; Satoshi Fukushima (+10 著者) Yoshihide Asano
      The British journal of dermatology (2024) Semantic Scholar
  5. 5. Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma. Kenji Yokota; Tatsuya Takenouchi; Yasuhiro Fujisawa; Satoshi Fukushima (+9 著者) Naoya Yamazaki
      The Journal of dermatology (2024) Semantic Scholar
  6. 6. Soluble PD-L1 predicts tumor response and immune-related adverse events in patients with advanced melanoma treated with anti-PD-1 antibodies. Kazumasa Oya; Yoshiyuki Nakamura; Larina Tzu-Wei Shen; Shoichiro Ishizuki (+1 著者) Yasuhiro Fujisawa
      The Journal of dermatology (2024) Semantic Scholar
  7. 7. Metastatic melanoma of the oral cavity showing prompt regression with the use of BRAF/MEK inhibitors. Kazumasa Oya; Shoichiro Ishizuki; Shiori Yasunaga; Yasuhiro FujisawaToshifumi Nomura
      The Journal of dermatology 51: e61-e62 (2024) Semantic Scholar
  8. 8. Cutaneous arteritis combined with antiphospholipid syndrome associated with the use of immune checkpoint inhibitors in a patient with a metastatic lung adenocarcinoma Maiko Hayashi; Ken Shiraishi; Satoshi Yoshida; Kazuki Yatsuzuka (+5 著者) Yasuhiro Fujisawa
      The Journal of Dermatology (2023) Semantic Scholar
  9. 9. Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol. Taku Fujimura; Koji Yoshino; Motoki Nakamura; Hiroshi Kato (+12 著者) Yoshihide Asano
      Experimental dermatology (2023) Semantic Scholar
  10. 10. Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study). Kenjiro Namikawa; Takamichi Ito; Shusuke Yoshikawa; Koji Yoshino (+30 著者) Naoya Yamazaki
      Cancer medicine (2023) Semantic Scholar
  11. 11. Adverse events associated with postoperative outcomes of adjuvant anti-PD-1 antibody therapy in both acral and non-acral cutaneous melanomas: A multicenter, observational, post hoc analysis study. Yusuke Muto; Yumi Kambayashi; Hiroshi Kato; Satoshi Fukushima (+11 著者) Taku Fujimura
      The Journal of dermatology (2023) Semantic Scholar
  12. 12. Postoperative adjuvant therapy for120 melanoma patients, including acral and mucosal subtypes: A multicenter, observational study of two-year follow-up results. Yusuke Muto; Yumi Kambayashi; Hiroshi Kato; Satoshi Fukushima (+12 著者) Taku Fujimura
      The British journal of dermatology (2023) Semantic Scholar
  13. 13. Combined use of nivolumab and ipilimumab among Japanese melanoma patients: Multi-center, retrospective study of 111 cases. Yasuhiro Fujisawa; Kenjiro Namikawa; Koji Yoshino; Yukiko Kiniwa (+15 著者) Takeo Maekawa
      The British journal of dermatology (2023) Semantic Scholar
  14. 14. Analyzing the relationship between the efficacy of first-line immune checkpoint inhibitors and cumulative sun damage in Japanese patients with advanced BRAF wild-type nonacral cutaneous melanoma: A retrospective real-world, multicenter study. Takashi Inozume; Kenjiro Namikawa; Hiroshi Kato; Shusuke Yoshikawa (+16 著者) Yasuhiro Nakamura
      Journal of dermatological science 110: 19 (2023) Semantic Scholar
  15. 15. Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases. Taku Fujimura; Takeo Maekawa; Hiroshi Kato; Takamichi Ito (+8 著者) Yoshihide Asano
      The Journal of dermatology (2023) Semantic Scholar
  16. 16. Eribulin mesylate exerts antitumor effects via CD103. Kazumasa Oya; Yoshiyuki Nakamura; Rei Watanabe; Ryota Tanaka (+7 著者) Yasuhiro Fujisawa
      Oncoimmunology 12: 2218782 (2023) Semantic Scholar
  17. 17. Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases. Yusuke Muto; Yumi Kambayashi; Hiroshi Kato; Satoshi Fukushima (+10 著者) Taku Fujimura
      Acta dermato-venereologica 102: adv00756 (2022) Semantic Scholar
  18. 18. Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin'. Kazumasa Oya; Yoshiyuki Nakamura; Yasuhiro Fujisawa; Toshifumi Nomura
      The British journal of dermatology 187: 275 (2022) Semantic Scholar
  19. 19. Loricrin Protects against Chemical Carcinogenesis. Tatsuya Ogawa; Yosuke Ishitsuka; Yoshiyuki Nakamura; Rei Watanabe (+4 著者) Toshifumi Nomura
      The Journal of investigative dermatology 142: 2023 (2022) Semantic Scholar
  20. 20. Keratinocyte apoptosis was present in clinically intact skin in a patient treated with enfortumab vedotin. Kazumasa Oya; Yoshiyuki Nakamura; Tomokazu Kimura; Hiroyuki NishiyamaYasuhiro Fujisawa
      European journal of cancer (Oxford, England : 1990) 167: 172 (2022) Semantic Scholar
1 2 3 … 12

書籍等出版物情報はまだありません。

講演・口頭発表情報はまだありません。

 1,389 total views